SRTA SRTA Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value at other companies

RepligenRGEN

$155.80—

AMN HealthcareAMN

$80.79-9.9%

KopinKOPN

$1.62—

Heartland ExpressHTLD

$10.71-5.1%

Cal-Maine FoodsCALM

$54.10+21.0%

Heartland ExpressHTLD

$10.48-4.3%

Other financials

Income statement

See full

Revenue$67.4M+87.4%

Gross profit$14.1M+100%

Operating income-$3.0M+47.7%

Net income$2.2M+162%

EPS (diluted)$0.03+175%

Balance sheet

See full

Cash & equivalents$59.0M+65.3%

Total debt$4.5M-50.7%

Total equity$285.7M+30.0%

Total assets$327.6M+30.8%

Cash flow

See full

Operating cash flow$3.9M+1,679%

CapEx$5.2M+98.1%

Free cash flow-$1.3M+54.8%

Valuation

See full

Market cap$463.78M+24.0%

Enterprise value$409.26M—

P/E8.9×—

P/S1.8×—

Profitability

See full

Gross margin21.7%+1.3pp

Operating margin-7.8%-2.8pp

Net margin21%+13.6pp

FCF margin-22.4%+1,712pp

Returns & leverage

See full

Return on equity15.6%+10.0pp

Debt / equity0×0.0×

Current ratio5.9×-1.0×

Where this comes from

Reported directly by SRTA in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue.

The official record: SRTA’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about SRTA's share based compensation arrangement by share based payment award equity instruments other than options nonvested weighted average grant date fair value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is SRTA's share based compensation arrangement by share based payment award equity instruments other than options nonvested weighted average grant date fair value?: SRTA (SRTA) reported share based compensation arrangement by share based payment award equity instruments other than options nonvested weighted average grant date fair value of $3.95 in Q1 2026.